Mechanism and ingredients prediction of Radix Salviae-Angelicae Sinensis Radix-Lycii Fructus-Rehmanniae Radix Praeparata-Ginkgo Folium for retinitis pigmentosa therapy using network pharmacology and molecular docking analysis.

Autor:	Wu J; Eye Institute, Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China., Sun Z; University of Rochester School of Medicine and Dentistry, Rochester, NY, USA., Zhang D; Eye Institute, Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China., Liu H; Eye Institute, Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China., Wu J; Eye Institute, Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Visual Impairment and Restoration, Science and Technology Commission of Shanghai Municipality, Shanghai, China.; State Key Laboratory of Medical Neurobiology, Institutes of Brain Science and Collaborative Innovation Center for Brain Science, Shanghai, China.; Key Laboratory of Myopia, Ministry of Health, Shanghai, China., Zhang S; Eye Institute, Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Visual Impairment and Restoration, Science and Technology Commission of Shanghai Municipality, Shanghai, China.; State Key Laboratory of Medical Neurobiology, Institutes of Brain Science and Collaborative Innovation Center for Brain Science, Shanghai, China.; Key Laboratory of Myopia, Ministry of Health, Shanghai, China.
Jazyk:	angličtina
Zdroj:	Annals of translational medicine [Ann Transl Med] 2023 Oct 25; Vol. 11 (11), pp. 382. Date of Electronic Publication: 2023 Oct 07.
DOI:	10.21037/atm-22-3557
Abstrakt:	Background: Radix Salviae (Danshen)- Angelicae Sinensis Radix (Danggui)- Lycii Fructus (Gouqizi)- Rehmanniae Radix Praeparata (Shudihuang)- Ginkgo Folium (Yinxinye) (RALRG) are commonly used herbs in China that have shown positive effects on retinitis pigmentosa (RP). However, little research has been performed on the impact of RALRG and RP. Herein, this study aimed to predict the mechanism and potential components of RALRG in treating RP. Methods: The ingredients of RALRG were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP); the potential targets of RP and RALRG were obtained from TCMSP, GeneCards, and the Online Mendelian Inheritance in Man (OMIM) database. A protein-protein interaction (PPI) network was constructed to visualize PPIs. The functional enrichment was performed with the R program. A visual RALRG-RP-pathway pharmacology network was established by Cytoscape 3.9.1. Molecular docking was used to perform molecular docking and calculate the binding affinity. Results: A total of 132 effective active ingredients in RALRG with 248 target genes were screened; 92 intersection target genes were acquired from the intersection of RP- and RALRG-related genes. Gene Ontology (GO) enrichment indicated that these intersection targets were mainly involved in oxidative stress, metal ion response, and chemical stress. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis indicated that the PI3K-AKT, cellular senescence, and MAPK signaling pathways were closely related to the therapy of RP. In addition, a potential pharmacology network for RALRG-RP-pathway was constructed. AKT1 and JUN were considered the primary targets. Luteolin, quercetin, and kaempferol were identified as the vital three active ingredients. Conclusions: RALRG was found to be the main regulator for oxidative stress and PI3K/AKT signaling pathways. Luteolin, quercetin, and kaempferol were three promising complementary ingredients for RP treatment. This study may provide a theoretical basis for applying RALRG to screen potential drugs for RP. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-3557/coif). All authors report the funding from National Natural Science Foundation of China (No. 81470625). The authors have no other conflicts of interest to declare. (2023 Annals of Translational Medicine. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu